vorinostat has been researched along with Hypophosphatemia in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Hypophosphatemia: A condition of an abnormally low level of PHOSPHATES in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma." | 9.30 | Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. ( Bandyopadhyay, D; Bose, P; Deng, X; Dent, P; Gordon, SW; Kmieciak, M; Lee, HM; Matherly, SC; McGuire, WP; Nguyen, T; Poklepovic, AS; Roberts, JD; Ryan, AA; Shafer, DA; Shrader, EE; Sterling, RK; Tombes, MB, 2019) |
| " A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma." | 5.30 | Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. ( Bandyopadhyay, D; Bose, P; Deng, X; Dent, P; Gordon, SW; Kmieciak, M; Lee, HM; Matherly, SC; McGuire, WP; Nguyen, T; Poklepovic, AS; Roberts, JD; Ryan, AA; Shafer, DA; Shrader, EE; Sterling, RK; Tombes, MB, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, SW | 1 |
| McGuire, WP | 1 |
| Shafer, DA | 1 |
| Sterling, RK | 1 |
| Lee, HM | 1 |
| Matherly, SC | 1 |
| Roberts, JD | 1 |
| Bose, P | 1 |
| Tombes, MB | 1 |
| Shrader, EE | 1 |
| Ryan, AA | 1 |
| Kmieciak, M | 1 |
| Nguyen, T | 1 |
| Deng, X | 1 |
| Bandyopadhyay, D | 1 |
| Dent, P | 1 |
| Poklepovic, AS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma[NCT01075113] | Phase 1 | 16 participants (Actual) | Interventional | 2010-08-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for vorinostat and Hypophosphatemia
| Article | Year |
|---|---|
Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemical and Drug I | 2019 |